Bioasis hires Colwell for IR services

2017-04-24 18:12 ET - News Release

Mr. Rob Hutchison reports

BIOASIS ANNOUNCES INVESTOR RELATIONS SERVICE AGREEMENT

Bioasis Technologies Inc. has entered into an investor relations agreement with 551943 Alberta Ltd., operating as Colwell Capital Corp., for a maximum term of 12 months commencing April 24, 2017. The company will pay Colwell $4,000 per month and will grant Colwell 175,000 stock options. The agreement and the option grant are subject to regulatory approval.

Rob Hutchison, executive chairman, commented: "We welcome Colwell on board. As the company, under new senior management leadership, enters this exciting phase, a formal investor communications program is must. We fully expect Colwell to provide that conduit to our shareholders."

About Bioasis Technologies Inc.

Bioasis Technologies is a biopharmaceutical company headquartered in the Vancouver, Canada, area, focused on overcoming the limitations of therapeutic drug delivery across the BBB. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders.

We seek Safe Harbor.